1. Home
  2. PLGO vs NBTX Comparison

PLGO vs NBTX Comparison

Compare PLGO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pelagos Insurance Capital Limited Common Shares

PLGO

Pelagos Insurance Capital Limited Common Shares

N/A

Current Price

$25.27

Market Cap

2.1B

Sector

Finance

ML Signal

N/A

Logo Nanobiotix S.A.

NBTX

Nanobiotix S.A.

HOLD

Current Price

$37.35

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLGO
NBTX
Founded
N/A
2003
Country
Bermuda
France
Employees
N/A
97
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
2015
2018

Fundamental Metrics

Financial Performance
Metric
PLGO
NBTX
Price
$25.27
$37.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
505.8K
155.1K
Earning Date
N/A
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$58.17
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$9.32
52 Week High
$26.34
$57.14

Technical Indicators

Market Signals
Indicator
PLGO
NBTX
Relative Strength Index (RSI) 54.24 46.41
Support Level $24.19 $35.59
Resistance Level $26.02 $41.06
Average True Range (ATR) 0.43 2.58
MACD 0.10 -0.60
Stochastic Oscillator 52.28 26.60

Price Performance

Historical Comparison
PLGO
NBTX

About PLGO Pelagos Insurance Capital Limited Common Shares

Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.

About NBTX Nanobiotix S.A.

Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

Share on Social Networks: